Structure of Vortioxetine HBr
CAS No.: 960203-27-4
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Vortioxetine HCl, a multimodal serotonergic agent, inhibits 5-HT1A, 5-HT1B, 5-HT3A, 5-HT7 receptor and SERT with IC50 of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively.
Synonyms: Lu AA21004 hydrobromide; Vortioxetine hydrobromide; Vortioxetine (hydrobromide)
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 960203-27-4 |
Formula : | C18H23BrN2S |
M.W : | 379.36 |
SMILES Code : | CC1=CC=C(SC2=CC=CC=C2N3CCNCC3)C(C)=C1.[H]Br |
Synonyms : |
Lu AA21004 hydrobromide; Vortioxetine hydrobromide; Vortioxetine (hydrobromide)
|
MDL No. : | MFCD22383961 |
InChI Key : | VNGRUFUIHGGOOM-UHFFFAOYSA-N |
Pubchem ID : | 56843850 |
GHS Pictogram: |
![]() ![]() ![]() |
Signal Word: | Danger |
Hazard Statements: | H360-H373-H410 |
Precautionary Statements: | P201-P202-P260-P273-P280-P308+P313-P391-P405-P501 |
Class: | 9 |
UN#: | 3077 |
Packing Group: | Ⅲ |
Description |
Vortioxetine is a multimodal serotonergic agent, inhibits 5-HT1A, 5-HT1B, 5-HT3A, 5-HT7 receptor and SERT with Ki values of 15 nM, 33 nM, 3.7 nM, 19 nM and 1.6 nM, respectively. Vortioxetine exhibits antagonist activity at 5-HT3A and 5-HT7 receptors, is a partial agonist at 5-HT1B receptors, an agonist at 5-HT1A receptors, and strongly inhibits SERT[1].
|
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT03555136 | - | Recruiting | June 30, 2020 | United States, Missouri ... More >> US 0039 Mattingly Recruiting Saint Charles, Missouri, United States, 63304 Contact: Email Contact via H. Lundbeck A/S Less << | |
NCT02386488 | Pharmacokinetics | Phase 1 | Completed | - | China ... More >> CB801 Chengdu, China Less << |
NCT02969876 | Depressive Disorder ... More >> Major Depression Depression Depression, Unipolar Less << | Phase 4 | Recruiting | November 2018 | United States, Massachusetts ... More >> the Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Kyle Palmstrom, B.S. 617-724-9458 kpalmstrom@mgh.harvard.edu Principal Investigator: Andrew Nierenberg, M.D. Less << |
NCT02327013 | - | Completed | - | - | |
NCT03187093 | Major Depressive Disorder | Phase 4 | Recruiting | September 2018 | Ukraine ... More >> State Institution "Zaporizhzhia Medical Academy of Postgraduate Education Ministry of Health of Ukraine" Recruiting Zaporizhzhia, Ukraine, 69096 Contact: Alexandra Troyan, MD +380673287519 troian@zmapo.edu.ua Less << |
NCT02871297 | Depressive Disorder, Major | Phase 3 | Enrolling by invitation | September 2019 | - |
NCT02072278 | Healthy Men | Phase 1 | Completed | - | France ... More >> FR801 Rennes, France, 35000 Less << |
NCT02272517 | Major Depressive Disorder | Phase 3 | Completed | - | Finland ... More >> FI005 Helsinki, Finland FI001 Kuopio, Finland FI006 Kupio, Finland FI007 Tampere, Finland FI004 Turku, Finland Germany DE005 Bochum, Germany DE004 Mittweida, Germany Serbia RS002 Belgrade, Serbia RS003 Belgrade, Serbia RS004 Belgrade, Serbia RS005 Belgrade, Serbia RS001 Kragujevac, Serbia Slovakia SK004 Bratislava, Slovakia SK001 Hronovce, Slovakia SK003 Levice, Slovakia SK002 Rimavska Sobota, Slovakia Less << |
NCT02327013 | Attention Deficit Hyperactivit... More >>y Disorder Less << | Phase 2 | Completed | - | United States, California ... More >> US015 Beverly Hills, California, United States US002 Garden Grove, California, United States US004 National City, California, United States United States, Florida US013 Bradenton, Florida, United States US006 Gainesville, Florida, United States United States, Georgia US010 Alpharetta, Georgia, United States United States, Illinois US014 Libertyville, Illinois, United States United States, Maryland US011 Baltimore, Maryland, United States United States, Massachusetts US009 Boston, Massachusetts, United States United States, Nevada US016 Las Vegas, Nevada, United States United States, New York US005 New York, New York, United States US008 New York, New York, United States United States, Texas US001 Austin, Texas, United States United States, Virginia US007 Herndon, Virginia, United States United States, Washington US003 Bellevue, Washington, United States Less << |
NCT02709746 | Depressive Disorder, Major | Phase 3 | Recruiting | April 2019 | - |
NCT03108625 | Depressive Disorder, Major | Phase 3 | Active, not recruiting | May 2020 | - |
NCT02279966 | Major Depressive Disorder | Phase 3 | Completed | - | Estonia ... More >> EE001 Tallinn, Estonia EE002 Tallinn, Estonia EE004 Voru, Estonia Finland FI002 Helsinki, Finland FI003 Helsinki, Finland FI001 Kuopio, Finland FI008 Oulu, Finland FI007 Tampere, Finland Germany DE002 Berlin, Germany DE001 Bielefeld, Germany DE003 Frankfurt, Germany DE007 Frankfurt, Germany DE008 Schwerin, Germany Lithuania LT002 Kaunas, Lithuania LT006 Palanga, Lithuania LT003 Silute, Lithuania LT001 Vilnius, Lithuania LT005 Vilnius, Lithuania Less << |
NCT02709655 | Depressive Disorder, Major | Phase 3 | Recruiting | May 2021 | - |
NCT02454426 | Major Depressive Disorder ... More >> Coronary Artery Disease Less << | Early Phase 1 | Withdrawn(PI left institution) | - | United States, Pennsylvania ... More >> Thomas Jefferson University Philadelphia, Pennsylvania, United States, 19107 Less << |
NCT02357797 | Schizophrenia ... More >> Negative Symptoms Less << | Phase 4 | Recruiting | March 2020 | United States, New York ... More >> The Zucker Hillside Hospital Recruiting Glen Oaks, New York, United States, 11004 Contact: Christoph U Correll, MD 718-470-4812 ccorrell@nshs.edu Less << |
NCT02528409 | Binge Eating Disorder | Phase 2 | Completed | - | United States, Illinois ... More >> University of Chicago Chicago, Illinois, United States, 60637 Less << |
NCT03598868 | Bipolar Disorder Depression | Phase 2 | Recruiting | September 25, 2021 | Korea, Republic of ... More >> Inha University Hospital Not yet recruiting Incheon, Korea, Republic of Contact: Hyeyoung Kim, MD Seoul National University Hospital Recruiting Seoul, Korea, Republic of Contact: Yong Min Ahn, MD. PHD Less << |
NCT02294305 | Social Anxiety Disorder ... More >> Major Depressive Disorder Less << | Phase 4 | Unknown | November 2016 | United States, New York ... More >> The Medical Research Network, LLC New York, New York, United States, 10128 Less << |
NCT02170220 | Severe Hepatic Impairment | Phase 1 | Completed | - | United States, Florida ... More >> University of Miami Miami, Florida, United States Less << |
NCT02279953 | Major Depressive Disorder | Phase 3 | Completed | - | Estonia ... More >> EE001 Tallinn, Estonia EE002 Tallinn, Estonia Finland FI002 Helsinki, Finland FI003 Helsinki, Finland FI005 Helsinki, Finland FI001 Kuopio, Finland FI006 Kupio, Finland FI004 Turku, Finland Germany DE002 Berlin, Germany DE001 Bielefeld, Germany DE005 Bochum, Germany DE003 Frankfurt, Germany DE004 Mittweida, Germany Serbia RS002 Belgrade, Serbia RS001 Kragujevac, Serbia Slovakia SK003 Levice, Slovakia SK002 Rimavska Sobota, Slovakia Less << |
NCT02170220 | - | Completed | - | - | |
NCT02972632 | Major Depressive Disorder | Phase 4 | Completed | - | United States, California ... More >> ATP Clinical Research, Inc. Costa Mesa, California, United States, 92626 ProScience Research Group Culver City, California, United States, 90230 Behavioral Research Specialists, LLC Glendale, California, United States, 91206 Pacific Research Partners Oakland, California, United States, 94607 Excell Research Oceanside, California, United States, 92056 Anderson Clinical Research Redlands, California, United States, 92374 University Medical Group Upland, California, United States, 91207 United States, Colorado MCB Clinical Research Centers, LLC Colorado Springs, Colorado, United States, 80910 United States, Florida Suncoast Clinical Research Inc. New Port Richey, Florida, United States, 34652 Behavioral Clinical Research , Inc North Miami, Florida, United States, 33162 Compass Research Main Orlando, Florida, United States, 32806 University of South Florida Tampa, Florida, United States, 33613 United States, Illinois Great Lakes Clinical Trials Chicago, Illinois, United States, 60640 Baber Research Group Naperville, Illinois, United States, 60563 United States, Indiana Deaconess Clinic Evansville, Indiana, United States, 47713-1227 United States, Massachusetts Novex Clinical Research, LLC New Bedford, Massachusetts, United States, 2740 Coastal Research Associates, Inc. South Weymouth, Massachusetts, United States, 2190 United States, Michigan University of Michigan, Ann Arbor Ann Arbor, Michigan, United States, 48109 United States, New York Columbia University Medical Center New York, New York, United States, 10023 United States, Ohio Dayton Clinical Research Dayton, Ohio, United States, 45406 United States, Pennsylvania Green & Seidner Family Practice Associates Lansdale, Pennsylvania, United States, 19446 United States, Texas Relaro Medical Trials Dallas, Texas, United States, 75243 Red Oak Psychiatry Associates, PA Houston, Texas, United States, 77090 Radiant Research, Inc. San Antonio, Texas, United States, 78229 Family Psychiatry of The Woodlands The Woodlands, Texas, United States, 77381 Less << |
NCT01491035 | Depressive Disorder ... More >> Anxiety Disorder Less << | Phase 2 | Completed | - | United States, District of Col... More >>umbia US003 Washington, District of Columbia, United States, 20010 United States, Kansas US004 Wichita, Kansas, United States, 67214 United States, Ohio US002 Cincinnatti, Ohio, United States, 45219 US001 Cleveland, Ohio, United States, 44106 Germany DE002 Berlin, Germany, 10249 DE001 Mainz, Germany, 55122 DE003 Ulm, Germany, 89075 Less << |
NCT01491035 | - | Completed | - | - | |
NCT03766867 | Major Depressive Disorder | Phase 2 | Recruiting | May 27, 2019 | Estonia ... More >> Tartu University Hospital (EE2002) Recruiting Tartu, Estonia Latvia Riga Centre of Psychiatry and Narcology (LV3002) Not yet recruiting Riga, Latvia Less << |
NCT00635219 | Major Depressive Disorder | Phase 3 | Completed | - | - |
NCT02371980 | Major Depressive Disorder | Phase 4 | Active, not recruiting | May 1, 2019 | - |
NCT00839423 | - | Completed | - | - | |
NCT00672620 | Major Depressive Disorder | Phase 3 | Completed | - | - |
NCT00839423 | Major Depressive Disorder | Phase 2 | Completed | - | - |
NCT00672620 | - | Completed | - | - | |
NCT01422213 | Major Depressive Disorder | Phase 3 | Completed | - | - |
NCT00730691 | Generalized Anxiety Disorder | Phase 3 | Completed | - | - |
NCT00730691 | - | Completed | - | - | |
NCT00635219 | - | Completed | - | - | |
NCT00811252 | Major Depressive Disorder | Phase 3 | Completed | - | - |
NCT00811252 | - | Completed | - | - | |
NCT01153009 | Depressive Disorder, Major | Phase 3 | Completed | - | - |
NCT01422213 | - | Completed | - | - | |
NCT01140906 | Major Depressive Disorder | Phase 3 | Completed | - | - |
NCT01153009 | - | Completed | - | - | |
NCT00744627 | Generalized Anxiety Disorder | Phase 3 | Completed | - | - |
NCT01140906 | - | Completed | - | - | |
NCT00734071 | Generalized Anxiety Disorder | Phase 3 | Completed | - | - |
NCT00744627 | - | Completed | - | - | |
NCT00734071 | - | Completed | - | - | |
NCT00731120 | - | Completed | - | - | |
NCT00735709 | Major Depressive Disorder | Phase 3 | Completed | - | - |
NCT00707980 | Major Depressive Disorder | Phase 3 | Completed | - | - |
NCT00735709 | - | Completed | - | - | |
NCT01163266 | Depressive Disorder, Major | Phase 3 | Completed | - | - |
NCT00707980 | - | Completed | - | - | |
NCT01179516 | Depressive Disorder, Major | Phase 3 | Completed | - | - |
NCT01163266 | - | Completed | - | - | |
NCT01255787 | Depressive Disorder, Major | Phase 2 Phase 3 | Completed | - | - |
NCT01255787 | - | Completed | - | - | |
NCT00731120 | Generalized Anxiety Disorder | Phase 3 | Completed | - | - |
NCT01299805 | - | Completed | - | - | |
NCT01488071 | Major Depressive Disorder | Phase 3 | Completed | - | - |
NCT01152996 | - | Completed | - | - | |
NCT01152996 | Depressive Disorder, Major | Phase 3 | Completed | - | - |
NCT01488071 | - | Completed | - | - | |
NCT01299805 | Healthy | Phase 1 | Completed | - | United States, California ... More >> Glendale, California, United States Less << |
NCT00596817 | Major Depressive Disorder | Phase 3 | Completed | - | - |
NCT01364649 | Treatment Outcome | Phase 3 | Completed | - | - |
NCT00596817 | - | Completed | - | - | |
NCT01607125 | Depression | Phase 1 | Completed | - | United Kingdom ... More >> GB001 Headington, United Kingdom, OX3 7JX Less << |
NCT01364649 | - | Completed | - | - | |
NCT01179516 | - | Completed | - | - | |
NCT00694304 | Major Depressive Disorder | Phase 3 | Completed | - | - |
NCT00761306 | Major Depressive Disorder | Phase 2 | Completed | - | - |
NCT00694304 | - | Completed | - | - | |
NCT00761306 | - | Completed | - | - | |
NCT01355081 | - | Completed | - | - | |
NCT01323478 | Major Depressive Disorder | Phase 3 | Completed | - | - |
NCT00788034 | Generalized Anxiety Disorder | Phase 3 | Completed | - | - |
NCT00672958 | Major Depressive Disorder | Phase 3 | Completed | - | - |
NCT01571453 | Major Depressive Disorder | Phase 3 | Completed | - | - |
NCT01355081 | Major Depressive Disorder | Phase 3 | Completed | - | Japan ... More >> Inzai-shi, Chiba, Japan Noda-City, Chiba, Japan Fukuoka-city, Fukuoka, Japan Kitakyushu-shi, Fukuoka, Japan Annaka-shi, Gunma, Japan Fujioka-shi, Gunma, Japan Takasaki-shi, Gunma, Japan Hatsukaichi-shi, Hiroshima, Japan Hiroshima-shi, Hiroshima, Japan Sapporo-Shi, Hokkaido, Japan Amagasaki-shi, Hyogo, Japan Kobe-shi, Hyogo, Japan Fujisawa-shi, Kanagawa, Japan Kawasaki-shi, Kanagawa, Japan Sagamihara-shi, Kanagawa, Japan Yokohama-shi, Kanagawa, Japan Osaka-shi, Kita-ku, Japan Kumamoto-shi, Kumamoto, Japan Kyoto-shi, Kyoto, Japan Kurashiki-shi, Okayama, Japan Osaka-shi, Osaka, Japan Fukaya-shi, Saitama, Japan Saitama-city, Saitama, Japan Utsunomiya-shi, Tochigi, Japan Anan-shi, Tokushima, Japan Tokushisma-shi, Tokushima, Japan Hachioji-shi, Tokyo, Japan Katsushika-ku, Tokyo, Japan Musashino-shi, Tokyo, Japan Nanyo-shi, Yamagata, Japan Ibaraki, Japan Tokyo, Japan Less << |
NCT01571453 | - | Completed | - | - | |
NCT01676571 | Healthy | Phase 1 | Completed | - | China ... More >> CN001 Tianjin, China, 300457 Less << |
NCT01323478 | - | Completed | - | - | |
NCT01395147 | Major Depressive Disorder | Phase 3 | Completed | - | Japan ... More >> Inzai-shi, Chiba, Japan Noda-City, Chiba, Japan Fukuoka-city, Fukuoka, Japan Kitakyushu-shi, Fukuoka, Japan Annaka-shi, Gunma, Japan Fujioka-shi, Gunma, Japan Takasaki-shi, Gunma, Japan Hatsukaichi-shi, Hiroshima, Japan Hiroshima-shi, Hiroshima, Japan Sapporo-Shi, Hokkaido, Japan Amagasaki-shi, Hyogo, Japan Kobe-shi, Hyogo, Japan Fujisawa-shi, Kanagawa, Japan Kawasaki-shi, Kanagawa, Japan Sagamihara-shi, Kanagawa, Japan Yokohama-shi, Kanagawa, Japan Osaka-shi, Kita-ku, Japan Kumamoto-shi, Kumamoto, Japan Kyoto-shi, Kyoto, Japan Kurashiki-shi, Okayama, Japan Osaka-shi, Osaka, Japan Fukaya-shi, Saitama, Japan Saitama-city, Saitama, Japan Utsunomiya-shi, Tochigi, Japan Anan-shi, Tokushima, Japan Tokushisma-shi, Tokushima, Japan Hachioji-shi, Tokyo, Japan Katsushika-ku, Tokyo, Japan Musashino-shi, Tokyo, Japan Nanyo-shi, Yamagata, Japan Ibaraki, Japan Tokyo, Japan Less << |
NCT00672958 | - | Completed | - | - | |
NCT01564862 | Depressive Disorder, Major | Phase 2 | Completed | - | - |
NCT03437564 | Healthy Adult Participants | Phase 1 | Completed | - | Japan ... More >> Nishi Kumamoto Hospital Kumamoto, Japan Less << |
NCT02389816 | Major Depressive Disorder | Phase 3 | Completed | - | Japan ... More >> Nagoya, Aichi, Japan Noda, Chiba, Japan Ruzan, Chiba, Japan Iizuka, Fukuoka, Japan Kitakyushu, Fukuoka, Japan Kurume, Fukuoka, Japan Kouriyama, Fukushima, Japan Shirakawa, Fukushima, Japan Sapporo, Hokkaido, Japan Ashiya, Hyogo, Japan Kanazawa, Ishikawa, Japan Kawasaki, Kanagawa, Japan Yokohama, Kanagawa, Japan Yokosuka, Kanagawa, Japan Kurashiki, Okayama, Japan Kadoma, Osaka, Japan Kita-ku, Osaka, Japan Osakasayama, Osaka, Japan Sakai, Osaka, Japan Karatsu, Saga, Japan Kawagoe, Saitama, Japan Kusatsu, Shiga, Japan Anan, Tokushima, Japan Arakawa-ku, Tokyo, Japan Chiyoda-ku, Tokyo, Japan Hachiouji, Tokyo, Japan Itabashi-ku, Tokyo, Japan Katsushika-ku, Tokyo, Japan Koutou-ku, Tokyo, Japan Meguro-ku, Tokyo, Japan Minato-ku, Tokyo, Japan Mitaka, Tokyo, Japan Musashino, Tokyo, Japan Nakano-ku, Tokyo, Japan Setagaya-ku, Tokyo, Japan Shibuya-ku, Tokyo, Japan Shinagawa-ku, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Suginami-ku, Tokyo, Japan Taito-ku, Tokyo, Japan Toshima-ku, Tokyo, Japan Kofu, Yamanashi, Japan Fukuoka, Japan Hiroshima, Japan Kumamoto, Japan Okayama, Japan Saitama, Japan Less << |
NCT01564862 | - | Completed | - | - |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.64mL 0.53mL 0.26mL |
13.18mL 2.64mL 1.32mL |
26.36mL 5.27mL 2.64mL |
|
Dissolving Methods |
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
|